Investing.com - Goldman Sachs (NYSE: GS) has resumed coverage on Rhythm Pharmaceuticals (NASDAQ: RYTM) with a Buy rating and a price target of $97.00. The stock, currently trading at $89, has shown ...

Analyst Ratings Published 10/07/2025, 12:16 0 Halozyme stock resumes coverage at Goldman Sachs with Neutral rating HALO 1.40% ...

American Airlines flights have resumed after a system outage grounded flights. Multiple reports on social media said planes were unable to take off because of technical problems.

Our Top 5 Analyst Questions Comfort Systems’s Q1 Earnings Call Alex Dwyer (KeyBanc Capital Markets) asked about the rationale for maintaining high-single-digit revenue guidance despite strong Q1 ...

Zinger Key Points Sunrun stock plunges after analyst says business depends on inflating system values to claim tax credits.

Stifel resumed coverage of Freshpet (NASDAQ:FRPT) on Thursday with a buy rating and a $90 price target, balancing near-term headwinds against long-term growth potential. Currently trading at $76. ...

They noted that even if generic supply resumes, the impact on Somatuline sales is not expected to be immediate. Deutsche Bank also pointed out the increasing investor interest in Ipsen’s long ...

San Francisco's Bay Area Rapid Transit (BART) system experienced a massive system-wide outage on Friday, due to a computer networking problem. All train services starting around 5 AM local time ...

After a day of remote learning in anticipation of possible flooding on Wednesday, students in Lafayette Parish will head back to school on Thursday, officials said.

Besides Wall Street's top -and-bottom-line estimates for Bentley Systems (BSY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared ...